FOSL1 and head and neck squamous cell carcinoma: Therefore, the down-regulation of FOSL1, PLAU, and VIM by the co-administration of cetuximab and apigenin may be considered as an innovative therapeutic strategy in the treatment and prevention of HNSCC in the future.